黏蛋白与黏液性卵巢癌：发生、鉴别诊断及治疗
Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment.
作者信息
Wang Yicong, Liu Lifeng, Yu Yongai
机构信息
Department of Obstetrics and Gynecology, Dalian Municipal Central Hospital, Dalian, China.
出版信息
Heliyon. 2023 Aug 17;9(8):e19221. doi: 10.1016/j.heliyon.2023.e19221. eCollection 2023 Aug.
Abstract
Mucinous ovarian carcinoma (MOC) is a rare histological type of epithelial ovarian cancer. It has poor response to conventional platinum-based chemotherapy regimens and PARPi-based maintenance treatment, resulting in short survival and poor prognosis in advanced-disease patients. MOC is characterized by mucus that is mainly composed of mucin in the cystic cavity. Our review discusses in detail the role of mucins in MOC. Mucins are correlated with MOC development. Furthermore, they are valuable in the differential diagnosis of primary and secondary ovarian mucinous tumors. Some types of mucins have been studied in the context of chemoresistance and targeted therapy for ovarian cancer. This review may provide a new direction for the diagnosis and treatment of advanced MOC.
摘要
黏液性卵巢癌（MOC）是上皮性卵巢癌中一种罕见的组织学类型。它对传统的铂类化疗方案和基于PARPi的维持治疗反应不佳，导致晚期疾病患者生存期短且预后不良。MOC的特征是囊肿腔内主要由黏蛋白组成的黏液。我们的综述详细讨论了黏蛋白在MOC中的作用。黏蛋白与MOC的发生相关。此外，它们在原发性和继发性卵巢黏液性肿瘤的鉴别诊断中具有重要价值。一些类型的黏蛋白已在卵巢癌的化疗耐药性和靶向治疗方面进行了研究。本综述可能为晚期MOC的诊断和治疗提供新的方向。
相似文献
1
Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment.
Heliyon. 2023 Aug 17;9(8):e19221. doi: 10.1016/j.heliyon.2023.e19221. eCollection 2023 Aug.
2
Mucinous Cancer of the Ovary: Overview and Current Status.
Diagnostics (Basel). 2020 Jan 19;10(1):52. doi: 10.3390/diagnostics10010052.
3
Survival of Patients With Mucinous Ovarian Carcinoma and Ovarian Metastases: A Population-Based Cancer Registry Study.
Int J Gynecol Cancer. 2015 Sep;25(7):1208-15. doi: 10.1097/IGC.0000000000000473.
4
Update on Prognostic and Predictive Markers in Mucinous Ovarian Cancer.
Cancers (Basel). 2023 Feb 12;15(4):1172. doi: 10.3390/cancers15041172.
5
Retrospective study of characteristics and hyperthermia intraperitoneal perfusion in mucinous borderline ovarian tumor and mucinous ovarian carcinoma.
Gland Surg. 2023 Apr 28;12(4):453-464. doi: 10.21037/gs-23-45. Epub 2023 Apr 13.
6
Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.
Virchows Arch. 2021 May;478(5):885-891. doi: 10.1007/s00428-020-02939-w. Epub 2020 Oct 3.
7
Options for the Treatment of Mucinous Ovarian Carcinoma.
Curr Treat Options Oncol. 2021 Nov 13;22(12):114. doi: 10.1007/s11864-021-00904-6.
8
Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125).
Mod Pathol. 2006 Oct;19(10):1386-94. doi: 10.1038/modpathol.3800646. Epub 2006 Jul 28.
9
Presentation and Prognosis of Primary Expansile and Infiltrative Mucinous Carcinomas of the Ovary.
J Clin Med. 2022 Oct 17;11(20):6120. doi: 10.3390/jcm11206120.
10
Multimodal diagnostic strategies and precision medicine in mucinous ovarian carcinoma: a comprehensive approach.
Front Oncol. 2024 Jul 8;14:1391910. doi: 10.3389/fonc.2024.1391910. eCollection 2024.
引用本文的文献
1
Mucinous Ovarian Carcinoma: Integrating Molecular Stratification into Surgical and Therapeutic Management.
Biomedicines. 2025 May 14;13(5):1198. doi: 10.3390/biomedicines13051198.
2
The role of macrophage polarization in ovarian cancer: from molecular mechanism to therapeutic potentials.
Front Immunol. 2025 Apr 22;16:1543096. doi: 10.3389/fimmu.2025.1543096. eCollection 2025.
3
Rare leptomeningeal recurrence of mucinous ovarian carcinoma.
Gynecol Oncol Rep. 2025 Apr 19;59:101749. doi: 10.1016/j.gore.2025.101749. eCollection 2025 Jun.
4
Postoperative metastatic Krukenberg tumors with and mutations in a patient with gastric cancer treated with oxaliplatin and tegafur: A case report.
Oncol Lett. 2025 Apr 2;29(6):262. doi: 10.3892/ol.2025.15008. eCollection 2025 Jun.
5
A 33.5 cm Mucinous Ovarian Carcinoma and Associated Comorbidities in an 89-Year-Old Female.
Cureus. 2024 Aug 27;16(8):e67970. doi: 10.7759/cureus.67970. eCollection 2024 Aug.
6
Management of open abdomen complication after laparotomy in an ovarian cancer patient with intraperitoneal metastasis.
J Surg Case Rep. 2024 Aug 6;2024(8):rjae482. doi: 10.1093/jscr/rjae482. eCollection 2024 Aug.
7
Oncogenic Pathways and Targeted Therapies in Ovarian Cancer.
Biomolecules. 2024 May 15;14(5):585. doi: 10.3390/biom14050585.
本文引用的文献
1
Mucin networks: Dynamic structural assemblies controlling mucus function.
Curr Opin Struct Biol. 2023 Apr;79:102524. doi: 10.1016/j.sbi.2022.102524. Epub 2023 Feb 6.
2
Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours.
BMC Cancer. 2023 Jan 13;23(1):44. doi: 10.1186/s12885-023-10533-x.
3
Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials.
Int J Gynecol Cancer. 2023 Jan 3;33(1):102-108. doi: 10.1136/ijgc-2022-003658.
4
Mucin 13 (MUC13) as a candidate biomarker for ovarian cancer detection: potential to complement CA125 in detecting non-serous subtypes.
Clin Chem Lab Med. 2022 Nov 17;61(3):464-472. doi: 10.1515/cclm-2022-0491. Print 2023 Feb 23.
5
A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary.
Int J Gynecol Cancer. 2022 May 3;32(5):662-668. doi: 10.1136/ijgc-2021-003104.
6
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.
ESMO Open. 2022 Feb;7(1):100311. doi: 10.1016/j.esmoop.2021.100311. Epub 2021 Dec 15.
7
Prognosis in primary mucinous ovarian carcinoma: focusing on the five pathological findings indicating metastatic mucinous carcinoma to the ovary.
J Gynecol Oncol. 2022 Mar;33(2):e18. doi: 10.3802/jgo.2022.33.e18. Epub 2021 Dec 6.
8
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Gynecol Oncol. 2021 Dec;163(3):473-480. doi: 10.1016/j.ygyno.2021.09.023. Epub 2021 Oct 6.
9
Decreased Gastric Gland Mucin-specific -glycans Are Involved in the Progression of Ovarian Primary Mucinous Tumours.
Acta Histochem Cytochem. 2021 Aug 25;54(4):115-122. doi: 10.1267/ahc.21-00032. Epub 2021 Jul 7.
10
MUC5AC expression is linked to mucinous/endometroid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer.
Pathol Res Pract. 2021 Aug;224:153533. doi: 10.1016/j.prp.2021.153533. Epub 2021 Jun 21.
Zotero 插件